Author

Komal Prem

Observed name: Prem, Komal

Observed institutions: Mayo Clinic, Apellis Pharmaceuticals (United States)

OpenAlex ID: A5063681576

Experimental Metabolic Syndrome Model Associated with Mechanical and Structural Degenerative Changes of the Aortic Valve

2018 · Jason L. Go, Komal Prem, et al. · Scientific Reports · 17

Wee1 kinase inhibitor adavosertib with radiation in newly diagnosed diffuse intrinsic pontine glioma: A Children’s Oncology Group phase I consortium study

2022 · Sabine Mueller, Tabitha Cooney, et al. · Neuro-Oncology Advances · 16

Pharmacokinetic/pharmacodynamic analysis of geographic atrophy lesion area in patients receiving pegcetacoplan treatment or sham

2024 · Ryan L. Crass, Komal Prem, et al. · CPT Pharmacometrics & Systems Pharmacology · 3

Pdct-04. Phase 1 Trial of Wee1 Kinase Inhibitor Azd1775 Combined With Radiation Therapy for Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma: a Report From the Children’s Oncology Group Phase 1 Pilot Consortium (advl1217)

2018 · Sabine Mueller, Xiaodong Yang, et al. · Neuro-Oncology · 3

Population Pharmacokinetics of Pegcetacoplan in Patients with Geographic Atrophy or Neovascular Age-related Macular Degeneration

2024 · Ryan L. Crass, Komal Prem, et al. · Ophthalmology Science · 2

Clinical Implications of Baseline-Corrected Total Immunoglobulin G Levels: Pharmacokinetic Data from a Phase 3, Open-Label Study of Patients with Primary Immunodeficiency Disease Treated with fSCIG 10%

2026 · Komal Prem, Courtney Moc Willeford, et al. · Journal of Human Immunity

Synthetic Polymers for Cell-Based Therapies

2018 · Komal Prem, Cole H. Fuerste, et al. · CRC Press eBooks

Works count: 8

Citation count: 41

H-index: 3

I10-index: 2